Zoetis Raises Guidance on Revenue Growth

Zoetis (ZTS) banal surged successful intraday trading Tuesday after nan institution hit second-quarter gross expectations and raised its full-year guidance.

The veterinary drugmaker now expects full-year gross of $9.1 cardinal to $9.25 billion, up from its anterior forecast of $9.05 cardinal to $9.2 billion. Analysts expect $9.12 billion, per Visible Alpha.

Q2 Revenue Tops Estimates, EPS Misses

For nan quarter, nan Parsippany, N.J.-based institution reported earnings per stock (EPS) of $1.37, down 6% year-over-year and beneath expectations, connected gross that accrued 8% to $2.36 billion, topping estimates. 

"We achieved 12% gross maturation successful nan U.S. and 10% operational gross maturation internationally, pinch some our companion animal and livestock portfolios seeing awesome world operational growth, 12% and 9% respectively," Chief Executive Officer (CEO) Kristin Peck said. 

Zoetis banal climbed astir 6% to $185.10 arsenic of 1 p.m. ET Tuesday.